FDA Approved: IBRANCE — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

The FDA approved a supplemental application for IBRANCE (palbociclib) submitted by Pfizer, resulting in an update to the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)

Snippet

SUPPL AP for IBRANCE (PALBOCICLIB)